Tanner C M, Chhablani R, Goetz C G, Klawans H L
Neurology. 1985 Jun;35(6):918-21. doi: 10.1212/wnl.35.6.918.
In a 12-month open-label trial, pergolide mesylate was administered in doses with antiparkinsonian efficacy to six patients with stable heart disease. Cardiac status did not worsen in any patient. Parkinson's disease improved in all patients. Pergolide is a safe and effective therapy for Parkinson's disease, even in patients with heart disease.
在一项为期12个月的开放标签试验中，对6名患有稳定心脏病的患者给予了具有抗帕金森病疗效剂量的甲磺酸培高利特。所有患者的心脏状况均未恶化。所有患者的帕金森病均有所改善。即使对于患有心脏病的患者，培高利特也是一种安全有效的帕金森病治疗药物。
